Skip to content

Interest of Flow Cytometry for the Diagnosis, the Follow up and Specific Immunotherapy (SIT) Arrest of Hymenoptera Venom Allergy

Interest of Flow Cytometry for the Diagnosis, the Follow up and SIT Arrest of Hymenoptera Venom Allergy

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00805402
Acronym
Cytoven
Enrollment
75
Registered
2008-12-09
Start date
2008-07-31
Completion date
2010-07-31
Last updated
2025-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergy

Brief summary

The aim of this study is to show that flow cytometry can be an accurate tool to help physicians regarding the diagnosis, the SIT decision and the SIT arrest of hymenoptera venom allergy. 75 patients having a story of reaction to hymenoptera venom will be selected for this trial. Blood samples will be analyzed at: inclusion visit, Week 1 visit, Week 3 visit, Week 10 and Week 21 visit.

Interventions

OTHERflow cytometry

flow cytometry

Sponsors

University Hospital, Limoges
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Adult patient (18 - 70 years) * Patient being informed and accepting to participate in the study with signature of informed consent * Patients having a clinical systematic and local, loco-regional story of reaction to the piqures of hymenopterans. * Patients treated by SIT for at least 5 years * Patients benefiting from a national insurance health

Exclusion criteria

* Children * Pregnant woman or who breast-feed * Patient under antihistaminic or corticoid for less than 8 days before the blood drawing * Protected Patient * Patient not having given his agreement after it was informed

Design outcomes

Primary

MeasureTime frame
% CD63 expression on basophil membrane by flow CytometryInclusion , Week 1, Week 3, Week 10 and Week 21 visits

Secondary

MeasureTime frame
Blood blocking factors levelWeek 1, Week 3, Week 10 and Week 21 visits

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026